Marketing medicinal products that facilitate the therapeutic relationship between care providers and patients has been the mission of Mike van Woensel since 2001 when he established Eurocept Pharmaceuticals.
Since 2013, the investment company Gimv originally listed on the Belgian stock exchange has been a partner of the Eurocept Group. At the time, Gimv, through its Health & Care Fund, acquired a minority holding along with founder/CEO Mike van Woensel. Until 2017 the group comprised homecare, private clinics and a pharmaceutical company. Since 2017 the company has been legally split. At that time Eurocept Pharmaceuticals Holding shed homecare and clinics. The cooperation between Gimv and Eurocept Pharmaceuticals is being used to further strengthen Eurocept’s position and to roll out the business model to neighboring countries.
Gimv is a European investment company, listed on Euronext Brussels. With 40 years’ experience in private equity, Gimv currently has EUR 2 billion of assets under management. The portfolio contains 55 portfolio companies, with combined turnover of EUR 2.5 billion and 14,000 employees. Gimv’s commitment to making a positive contribution to society has been demonstrated amongst others through the recent successful issue of a sustainable bond.
As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial, innovative companies with high growth potential and supports them in their transformation into market leaders. Gimv’s four investment platforms are Consumer, Health & Care, Smart Industries and Sustainable Cities. Each platform works with an experienced team across Gimv’s home markets of Benelux, France and DACH, supported by an extended international network of experts.
See also: www.gimv.com and https://www.gimv.com/en/portfolio/eurocept-pharmaceuticals